Novo Nordisk Pharmaceutical Servicessp. z o.o.

Wholesale of pharmaceutical goods

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-09-12
Share capital
6,050,000.00 PLN
Registered address
ul. Krakowiaków 46, 02-255 Warszawa, Poland
Phone
Social media
Electronic delivery address
AE:PL-97786-43172-BEFSC-14

Financials

Revenue history (in m)

From the notes

Current income tax (CIT due)$1,777,406

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 47 days late). All were audited by a statutory auditor.

  • 202506/07/2026
  • 202412/06/2025
  • 202301/07/2024
  • 202206/06/2023
  • 202131/08/2022
  • 202001/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Industry · Wholesale of pharmaceutical goods14 / 1,141
Top 1.2%
Division · Wholesale trade63 / 19,982
Top <1%
City · Warszawa167 / 56,958
Top <1%
Voivodeship · Mazowieckie199 / 77,118
Top <1%
Country · Poland482 / 297,873
Top <1%

Results vs industry

Revenue
This companyUSD 405.74mMedianUSD 1.07mAverageUSD 22.38m
Net profit
This companyUSD 6.87mMedianUSD 37.89kAverageUSD 879.28k
Operating costs
This companyUSD 397.07mMedianUSD 929.75kAverageUSD 21.06m
Assets
This companyUSD 261.75mMedianUSD 609.81kAverageUSD 11.84m

Offer

  • Antidiabetic medicines
  • Medicines for chronic diseases
  • Medicine injection pens

Public procurement

10 tenders recorded as contractor, with a total value of $51,575,418.

SubjectAmount
Recombinant coagulation factor VIIa concentrate, including delivery to Regional Blood Donation and Blood Treatment Centres; procedure reference: ZZP.ZP.411.122.2026
$10.7M
Recombinant coagulation factor VIIa concentrate, including delivery to Regionalne Centra Krwiodawstwa i Krwiolecznictwa; procedure reference: ZZP.ZP.411.79.2026
$5.7M
Supply of Conicizumabum and Vamorolonum medicines (RDTL)
$280.1K

Authorized Representatives

Cédric Jean-Paul Molla – Management Board Member
Sławomir Dominik Stachowicz – Attorney-in-fact (sole)
Jose Garcia Eboli – Management Board Member
Magdalena Edyta Paradzińska – Attorney-in-fact (sole)
Katarzyna Magdalena Kacperska – Management Board Member

Manner of representation

Each member of the management board is authorised to represent the company independently.

Ownership

OwnerSharesShare valueStake
Novo Nordisk Region Europe A/s
12,099$1,634,116.6999.9917%
Others
1$135.060.0083%

Beneficial owners

Person

Bank accounts

Registered as a VAT taxpayer on 2004-08-01.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Competitors

Name
Essity Polandsp. z o.o.
Centrala Farmaceutyczna CefarmS.A.
Bausch Health Polandsp. z o.o.
Komtur Polskasp. z o.o.
Sanofisp. z o.o.
Novartis Polandsp. z o.o.
USP Zdrowiesp. z o.o.
MSD Polska Dystrybucjasp. z o.o.
Pfizer Trading Polskasp. z o.o.
Berlin-Chemie / Menarini Polskasp. z o.o.

Change history

DateEvent
2025-12-03Switch to PKD 2025
2018-11-07Address change
2018-02-02Address change
2015-12-15Address change
2015-07-17PKD change

FAQ

Last updated: 2026-10-04